Biopharmaceutics is a pivotal field within the Food and Drug Administration's (FDA) purview, where the intersection of biology and pharmaceuticals takes center stage. This discipline focuses on the study of how drugs are absorbed, distributed, metabolized, and excreted by the body, with a keen eye on the biological factors influencing drug performance.
The FDA plays a crucial role in evaluating the safety and efficacy of biopharmaceuticals, ensuring that these innovative drugs meet rigorous standards before reaching the market. This involves a comprehensive assessment of the biological and chemical properties of these compounds, understanding their behavior in the human body, and predicting their therapeutic impact.
The dynamic landscape of biopharmaceutics aligns with the FDA's commitment to advancing public health by fostering the development of cutting-edge therapies. By staying at the forefront of scientific advancements, the FDA continues to navigate the evolving terrain of biopharmaceutics, contributing to the approval of novel, life-changing treatments that meet the highest standards of quality and effectiveness.
Yong Xiao Wang
Albany Medical College, United States
Consolato M Sergi
Universities of Alberta and Ottawa, Canada
Vladlen Slepak
University of Miami Miller School of Medicine, United States
Andreas M Papas
Antares Health Products, United States
Axel H Schonthal
University of Southern California, United States
Bernd Blobel
University of Regensburg, Germany
Srividya Narayanan
Northeastern University, United States
Daisy Mills
University College London, United Kingdom
Maria Richards Brown
University College London, United Kingdom
Gurpreet Singh
IQVIA, United KingdomSubmit your abstract Today
Title : Medical liver biopsy: Toward a personalized approach
Consolato M Sergi, Universities of Alberta and Ottawa, Canada
Title : Emerging formulation and delivery applications of vitamin E TPGS
Andreas M Papas, Antares Health Products, United States
Title : Ectopically expressed olfactory receptors as an untapped family of drug targets and discovery of agonists and antagonists of OR51E1, an understudied G protein-coupled receptor
Vladlen Slepak, University of Miami Miller School of Medicine, United States
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model through de-sign-inspired biotech- & biopharma-driven applications and upgraded business mar-keting to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Innovative development and delivery of biologics for chronic obstructive pulmonary disease
Yong Xiao Wang, Albany Medical College, United States
Title : Mathematical modeling the disc diffusion test: Antibacterial activity of copper-doped SnO2
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Antibody-proteases as translational tools of the next-step generation to be applied for biopharmacy-related and precision medical practice
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Storage stability and solution binding affinity of an fc-fusion mimetic
Hanieh Khalili, University of East London, United Kingdom
Title : Macitentan/tadalafil combination– An additional value in pharmacotherapy of pulmonary arterial hypertension
Miroslav Radenkovic, University of Belgrade, Serbia